Nasdaq
$3.96▲ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.27BShares out 3.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
2- 8.11After-hours26.08.12 05:0710-QEarnings#●●●#●●●
Taysha Gene Therapies, Inc.
테이샤 진 테라피스(Taysha Gene Therapies)는 2026년 6월 30일 기준 분기 보고서(10-Q)를 통해 재무 상태와 운영 현황을 공시했습니다. 해당 보고서에는 아스텔라스(Astellas)와의 라이선스 계약, 트리니티(Trinity) 대출 약정, 그리고 주식 기반 보상 계획 등 회사의 주요 자본 조달 및 운영 활동이 포함되었습니다.…more
$3.96+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.11After-hours26.08.12 05:058-KKey event
Taysha Gene Therapies, Inc.
테이샤 진 테라피스는 2026년 2분기 실적 발표를 통해 4,660만 달러의 순손실과 주당 0.13달러의 손실을 기록했습니다. 레트 증후군 치료제 TSHA-102의 임상 투약을 완료했으며, 2027년 상반기 중 6개월 중간 분석 데이터 발표 및 FDA와의 BLA 제출 경로 논의를 예정하고 있습니다. 또한 2억 3,000만 달러 규모의 유상증자를 완료하여 2028년 하반기까지 운영 자금을 확보했습니다.…more
$3.96+0.13%vs prev closeView filingShare
1 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2Pre-market26.10.02 21:00#●●●
Taysha Gene Therapies Grants Equity Awards to New Employees
Taysha Gene Therapies announced the grant of restricted stock units and stock options to four new employees as an inducement for their hiring. This is a standard compensation procedure for talent acquisition and has no immediate material impact on the stock price.…more
$3.96+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1Pre-market26.10.01 21:00
●●●●●●●● ●●●●● ●●●●●●
Taysha Gene Therapies will present encore data from its Phase 1/2 clinical trial of TSHA-102 for Rett syndrome at the 55th Child Neurology Society Annual Meeting. These presentations reiterate previously shared findings and do not represent new clinical milestones.…more
$3.96+0.13%vs prev close - 9.4Pre-market26.09.04 21:00
●●●●●●●● ●●●●● ●●●●●●
Taysha Gene Therapies has granted restricted stock units and stock options to five new employees as an employment inducement. This is a standard corporate compensation practice and does not have a material impact on the company's valuation.…more
$3.96+0.13%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report